Cellution Biologics Inc.

What Cellution Biologics Inc. does

Cellution Biologics Inc. is a privately held regenerative biologics company founded in 2024 and headquartered in Roswell, Georgia. The company develops, processes, and supplies a portfolio of human placental tissue-based allograft products — primarily dehydrated (dHAICM) and lyophilized amnion-intermediate layer-chorion membrane grafts — for advanced wound care (chronic wounds, diabetic foot ulcers, burns, surgical wounds) and ocular surface repair. The core portfolio includes AmchoPlast, AmCoreMatrix, OptiCover, and the recently launched AmnioPlast 1 and AmnioPlast Double. Manufacturing is backed by what the company describes as the world's largest GMP-certified processing of placental tissues, with products processed using the proprietary AGNES technology and certified under ISO 9001, ISO 13485, AATB, AABB, and CAP.\n\nThe company operates a field-based enterprise sales model targeting hospitals, wound care centers, ambulatory surgery centers, IDNs, GPOs, ophthalmology and optometry practices, and academic medical centers across the United States. Ordering is conducted via direct customer service email and a Shopify-based online storefront, with revenue generated per unit through invoicing and net-30 payment terms. The company also operates a distributor channel with a dedicated portal and entered a co-marketing partnership with CHUM Health to provide reimbursement support (insurance verification, prior authorization, coding, claims management) for the Elite Graft Program. Products are regulated as HCT/Ps under 21 CFR Part 1271 and are not FDA-approved or cleared.\n\nIn July 2026, Cellution Biologics signed a definitive agreement to acquire the SimpliDerm human hydrated acellular dermal matrix business from Elutia Inc. for $8 million at closing plus up to $3 million in milestone payments over 18 months, marking its entry into the $1.5 billion U.S. breast reconstruction and plastic/reconstructive surgery market. SimpliDerm brings established commercial adoption, existing reimbursement coverage, and relationships with reconstructive surgeons, hospitals, GPOs, and IDNs. Interim results from two randomized multicenter studies (ELITE and CAMPLIFE), published in the Cureus journal in December 2025, demonstrated 71% complete wound closure and 78% wound area reduction in diabetic foot ulcer patients using AmchoPlast plus standard care, compared to 23% and 38% respectively with standard care alone.

Name

Cellution Biologics Inc.

Legal name

Cellution Biologics Inc.

Website

https://www.cellutionbiologics.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Cellution Biologics develops and supplies human placental tissue-based allograft products for wound care and ocular surface repair, with the SimpliDerm acquisition expanding into reconstructive surgery. Products are sold via field sales, distributors, and e-commerce to U.S. healthcare providers.

Ownership category

akta.pro rank

Product category

Regenerative Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Ophthalmic Goods Manufacturing (339115)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industries

Ophthalmic Regeneration (cornea/retina) (HLAAAGAK), Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK), Acellular/Decellularized Matrices & ECM Products (HLAAAGAF)

Keywords

• Human tissue allografts
• Regenerative biologics
• Wound care allografts
• Ocular surface repair
• Placental tissue processing

Headquarters

HQ city

Roswell

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Biologic Allograft Product Sales: One-time sale of human tissue-based allograft products (AmchoPlast, AmCoreMatrix, OptiCover, and following closing SimpliDerm) to healthcare providers including hospitals, wound care centers, ophthalmology and optometry practices, and ambulatory surgery centers. Revenue is generated per unit with invoicing and 30-day payment terms.
2. Acquisition of SimpliDerm Business: Cellution acquired SimpliDerm human hydrated acellular dermal matrix business from Elutia Inc. for $8 million cash at closing plus up to $3 million in milestone payments over 18 months. This acquisition marks Cellution's entry into the U.S. reconstructive surgery market and expands revenue streams beyond wound care and ocular repair.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Cellution Biologics develops, manufactures, and distributes human placental tissue-based allograft products — primarily dehydrated and lyophilized amnion-intermediate layer-chorion membrane (dHAICM) grafts — for advanced wound care, burn and surgical reconstruction, and ocular surface repair. Following the 2026 acquisition of SimpliDerm from Elutia Inc., the company also distributes a hydrated human acellular dermal matrix for plastic and reconstructive surgery, selling primarily to hospitals, wound care centers, ophthalmology and optometry practices, ambulatory surgery centers, and GPOs/IDNs across the United States.

Product overview

Cellution Biologics Inc. offers a portfolio of human placental tissue-based allograft products primarily for advanced wound care and ocular repair applications. The core wound cover portfolio includes AmchoPlast (dehydrated dHAICM), AmchoPlast FD (lyophilized version), AmCoreMatrix, and AmCoreMatrix FD (hospital-grade versions), all derived from human amnion-intermediate layer-chorion membrane. The ocular grafts portfolio includes OptiCover (lyophilized amnion membrane disc). In late 2025, the company launched AmnioPlast 1 and AmnioPlast Double for ocular surface repair. The portfolio was significantly expanded through the 2026 acquisition of SimpliDerm (hydrated human acellular dermal matrix from Elutia Inc.), marking Cellution Biologics' entry into the U.S. reconstructive surgery market beyond wound care and ocular repair. The products are built by the world's largest GMP-certified processor of placental tissues and are intended for homologous use in clinical applications.

Differentiator

Problem solved

Functional benefit

Products and services

• AmchoPlast Sterile dehydrated Human Amnion – Intermediate Layer – Chorion Membrane Allograft (dHAICM) processed using AGNES proprietary technology to preserve therapeutic properties for wound cover applications in clinical and office settings. Available in 18 sizes.
• AmchoPlast FD Lyophilized (freeze-dried) Human Amnion – Intermediate Layer – Chorion Membrane Allograft for wound cover applications, offering extended shelf life and room temperature storage convenience. Available in 18 sizes.
• AmCoreMatrix Dehydrated Human Amnion – Intermediate Layer – Chorion Membrane Allograft designed for hospital use wound cover applications. Available in 27 sizes for diverse wound care needs.
• AmCoreMatrix FD Lyophilized Human Amnion – Intermediate Layer – Chorion Membrane Allograft for hospital use wound cover applications. Available in 20 sizes.
• OptiCover Lyophilized Amnion Membrane Disc Allograft for ocular surface repair that preserves the HC-HA/PTX3 bioactive complex, features a ringless design for patient comfort, and can be stored at room temperature (15°C–30°C). Aseptically processed and terminally sterilized via gamma irradiation.
• AmnioPlast 1 Dehydrated human amnion membrane allograft for ocular surface repair following reconstruction procedures, offering ready-to-use convenience in clinic and operating-room settings.
• AmnioPlast Double Dehydrated human amnion membrane allograft for ocular surface repair following reconstruction procedures, offering ready-to-use convenience in clinic and operating-room settings.
• SimpliDerm Hydrated human acellular dermal matrix for plastic and reconstructive surgery, including breast reconstruction and soft tissue repair. An established product with commercial adoption, reimbursement coverage, and existing relationships with reconstructive surgeons, hospitals, GPOs, and IDNs across the United States.

Quantifiable outcome

• 71% of patients receiving AmchoPlast plus standard of care achieved complete wound closure vs 23% with standard care alone
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• CHUM HealthcoreGTM or Marketing Partner · 19 November 2025CHUM Health is a reimbursement expertise partner that backs every treatment with dedicated support from insurance verification and prior authorization to coding, documentation, claims management, compliance, and revenue protection. The partnership combines Cellution's advanced biologic wound care portfolio with CHUM Health's Elite Graft Program, providing revenue assurance support and a deferred payment model. The collaboration is marketed as 'Clinical innovation. Reimbursement expertise. One partnership working for your practice.'

Scale indicators5 records

Recent moves4 records

Expansion highlights5 records

Emerging players

• AlloSource: AlloSource is a non-profit tissue bank distributing amniotic membrane (AlloWrap) and dermal allografts for wound care, burn, and surgical applications. It is a peer in placental tissue allografts with overlapping clinical applications and customer base.

Broad incumbents

• ConvaTec: ConvaTec is a global wound care and ostomy company with an advanced wound care franchise including Avelle, AQUACEL, and biologic allograft partnerships. It is a broad incumbent in the wound care category where Cellution is gaining share.
• Integra LifeSciences: Integra LifeSciences is a large medical device company with a regenerative tissue technologies portfolio (Integra Dermal Regeneration Template, AmnioExcel, BioD) spanning wound care, reconstructive surgery, and surgical applications. It competes with Cellution across both wound care and, post-SimpliDerm, reconstructive surgery with an established hospital and IDN sales channel.
• MTF Biologics: MTF Biologics is one of the largest U.S. tissue banks, distributing placental, dermal, and other allografts (AmnioBand, AlloPatch, DermaPure) to wound care, surgical, and sports medicine providers. It is a long-standing incumbent in the same placental tissue value chain as Cellution.
• Coloplast (Wound & Skin Care): Coloplast's Wound & Skin Care division offers Biatain and other advanced wound dressings, plus through partnerships/sales, competes in the advanced biologics space. It is a broad incumbent selling to the same wound care providers and hospital systems as Cellution.
• Smith+Nephew: Smith+Nephew is a global medical device company with a substantial advanced wound management portfolio (PICO, RENASYS, ALLEVYN, GRAFIX) and a biologic allograft franchise. It competes with Cellution in wound care settings and at hospital formularies.

Direct peers

• MiMedx Group: MiMedx is the largest U.S. processor of placental tissue allografts (EpiFix, AmnioFix) for wound care and surgical applications. It is the most direct comparable to Cellution Biologics given overlapping product platforms, target customers (wound care centers, surgeons, IDNs), and reliance on dehydrated amnion/chorion membrane technology.
• Amniox Medical (Halozyme): Amniox markets CLARIX and other cryopreserved amniotic membrane products for wound care, ophthalmology, and orthopedic applications. It is one of the closest direct competitors in placental tissue allografts and shares Cellution's go-to-market through specialty surgeons and ophthalmologists.
• Organogenesis Holdings: Organogenesis sells Apligraf, Dermagraft, and a portfolio of amnion-based wound care and surgical biologics (NuShield, Affinity) to hospitals, wound care centers, and physician offices. It directly competes with Cellution in advanced wound care and shares the same HCT/P regulatory pathway and channel structure.
• Tela Bio: Tela Bio markets OviTex and other biologic matrices for hernia, abdominal wall reconstruction, and plastic surgery. It is a direct peer to Cellution in the post-SimpliDerm reconstructive surgery and dermal matrix category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cellution-biologics

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellution Biologics Inc.